Stay updated on IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, representing an adjustment in the recommended dose for safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of IMO-2125 when administered in combination with ipilimumab in patients with metastatic melanoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:38.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients with metastatic melanoma, specifying the required disease stage, prior treatments, and other health conditions. Previously, this section only indicated that no information was provided.
    Difference
    37%
    Check dated 2024-05-22T21:22:05.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:54:42.000Z thumbnail image

Stay in the know with updates to IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.